This stock could be a wealth destroyer in the next five years.

NEW YORK (WABC) -- The biotechnology company Novavax plans to submit complete data to the US Food and Drug Administration soon for possible emergency use authorization of its coronavirus vaccine, CEO ...

Nuvaxovid™ is the only protein-based, non-mRNA COVID-19 vaccine available in the U.S. for the 2025-2026 vaccination season "With today's approval, we will work with our partner Sanofi to provide ...

There may soon be another COVID-19 vaccine on the market in the U.S. Novavax announced Monday that it has submitted a request to the Food and Drug Administration for emergency use authorization for ...

The Food and Drug Administration (FDA) signed off Wednesday on an emergency use authorization for the Novavax COVID-19 vaccine for individuals 18 years of age and older. The Novavax vaccine is protein ...

Novavax says its COVID-19 vaccine is proving safe and effective for kids as young as 12. The Maryland-based company makes a protein-based vaccine that's been cleared for use in adults in parts of the ...

A recent study has provided the first side-by-side comparison of how three major COVID-19 vaccine types differ in triggering ...

SEATTLE, June 3, 2020 /PRNewswire/ -- AGC Biologic s, a global biopharmaceutical Contract Development and Manufacturing Organization (CDMO), has announced that it will partner with Novavax, Inc.